Accord Healthcare announced the acquisition of Ewing, NJ-based Essential Pharmaceuticals. Under the terms of the agreement, along with the Essential company, Accord has acquired the rights to sell Custodiol HTK Solution in the United States and Canada. Custodiol HTK Solution is a leading organ preservation solution indicated for perfusion and flushing of donor kidneys, liver, pancreas and heart prior to and after removal from donor.
“We are thrilled to be expanding on our capabilities of providing life-saving, affordable medicines and therapies to patients and healthcare providers alike. Custodiol HTK is a vital product in the organ donation process and we are excited to include it in our product offering, as well as build upon the research and development programs in place for future organ preservation drug products,” said Gerald Price, president of Accord Healthcare.
Commenting on the acquisition, Allan Weber, former CEO of Essential said: “As a growth oriented company, we couldn’t have found a better partner than Accord Healthcare. Valued Custodiol HTK customers can expect to see the same familiar faces of our transplant specialists, as well as experience the same outstanding customer service to which they have grown accustomed.”
Accord Healthcare is the 12th largest generic pharmaceutical firm in the United States, per IMS Health. The company’s U.S. headquarters is in Durham, NC. It is a part of the Intas Group, headquartered in Ahmedabad, India.
(Source: PR Newswire)
